^
    Back
    Association details:
    Biomarker:ATP7A overexpression
    Cancer:Hepatocellular Cancer
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Int Immunopharmacol
    Title:

    Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma

    Published date:
    12/08/2022
    Excerpt:
    ...HCC patients with high ATP7A levels were more sensitive to sorafenib and demonstrated higher survival rates after sorafenib treatment.
    DOI:
    10.1016/j.intimp.2022.109518